Alembic Pharmaceuticals Intrinsic Value
Alembic Pharmaceuticals (APLLTD) median intrinsic value is ₹1668.90 from 10 valuation models (range ₹264–₹2086), vs current price ₹834.45 — +100.0% upside (Trading Below Calculated Value), margin of safety 50.0%. For current market price and key ratios, visit Alembic Pharmaceuticals screener.
APLLTD Valuation Methods Summary — DCF, Graham Number & P/E
Alembic Pharmaceuticals intrinsic value across 10 models vs current price ₹834.45 — upside/downside and value range per method. Analyse Alembic Pharmaceuticals ownership pattern to track promoter, FII and institutional holdings.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹907.28 | ₹725.82 - ₹1088.74 | +8.7% | EPS: ₹41.24, Sector P/E: 22x |
| Book Value Method | asset | ₹2086.12 | ₹1877.51 - ₹2294.73 | +150.0% | Book Value/Share: ₹1453.59, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹1668.90 | ₹1502.01 - ₹1835.79 | +100.0% | Revenue/Share: ₹1922.05, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹1668.90 | ₹1502.01 - ₹1835.79 | +100.0% | EBITDA: ₹920.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹2086.12 | ₹1668.90 - ₹2503.34 | +150.0% | CF Growth: 9.1%, Discount: 15% |
| PEG Ratio Method | growth | ₹263.94 | ₹237.55 - ₹290.33 | -68.4% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹637.16 | ₹573.44 - ₹700.88 | -23.6% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹1668.90 | ₹1502.01 - ₹1835.79 | +100.0% | ROE: 14.3%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹1161.37 | ₹1045.23 - ₹1277.51 | +39.2% | EPS: ₹41.24, BVPS: ₹1453.59 |
| Dividend Yield Method | dividend | ₹480.00 | ₹432.00 - ₹528.00 | -42.5% | DPS: ₹12.00, Target Yield: 2.5% |
APLLTD Intrinsic Value vs Market Price — All Valuation Models
Alembic Pharmaceuticals fair value range ₹264–₹2086 vs current market price ₹834.45 across 10 valuation models. Read APLLTD ex-dividend dates for the complete payout history and dividend yield track record.
APLLTD Intrinsic Value Analysis — Undervalued or Overvalued?
Alembic Pharmaceuticals median intrinsic value ₹1668.90, current price ₹834.45 — Trading Below Calculated Value by 100.0%, margin of safety 50.0%.
What is the intrinsic value of APLLTD?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Alembic Pharmaceuticals (APLLTD) is ₹1668.90 (median value). With the current market price of ₹834.45, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹263.94 to ₹2086.12, indicating ₹263.94 - ₹2086.12.
Is APLLTD undervalued or overvalued?
Based on our multi-method analysis, Alembic Pharmaceuticals (APLLTD) appears to be trading below calculated value by approximately 100.0%.
APLLTD Financial Health — Key Ratios vs Industry Benchmarks
Alembic Pharmaceuticals financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 9.09 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 14.3% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 11.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.86x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
APLLTD Cash Flow Quality — Operating & Free Cash Flow
Alembic Pharmaceuticals operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹783 Cr | ₹530 Cr | Positive Free Cash Flow | 8/10 |
| March 2025 | ₹88 Cr | ₹-196 Cr | Positive Operating Cash Flow | 6/10 |
| March 2024 | ₹803 Cr | ₹643 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹724 Cr | ₹500 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹552 Cr | ₹366 Cr | Positive Free Cash Flow | 8/10 |